|
- Home | Biogen
Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities
- Company | Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities
- Our U. S. Legacy | Biogen
Headquartered in Cambridge, Massachusetts, Biogen is one of the oldest independent American biotechnology companies We are North Carolina’s largest biotech employer and among the top five biopharmaceutical employers in the state, where our primary manufacturing operations are located
- Careers | Biogen
Everyone at Biogen contributes to our mission to create transformative medicines for people who need them the most Explore our business areas to discover where you can make an impact on our team
- Biogen and City Therapeutics Announce Strategic Research Collaboration . . .
CAMBRIDGE, Mass , May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc (Nasdaq: BIIB) and City Therapeutics, Inc , a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced a strategic collaboration to develop select novel RNAi therapies
- Mission and Culture - Biogen
Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities
- Biogen Announces Plans for New Global Headquarters and Innovation Hub . . .
Biogen plans to be the sole corporate tenant in the building, allowing the company to optimize its real estate footprint in Cambridge and create a purpose-built innovation hub designed to foster increased collaboration among employees and external partners
- Biogen and Stoke Therapeutics Enter into Collaboration to Develop and . . .
Biogen receives exclusive rights to commercialize zorevunersen in the rest of the world Upon closing of this transaction, Stoke will receive an upfront payment of $165 million The parties will share external clinical development costs for zorevunersen (30 percent Biogen; 70 percent Stoke)
|
|
|